Celularity Inc
For the period ended Sep 30, 2024. Filed Dec 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Dec 6, 2024
CELU$0.71-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
| Nine Months Ended September 30, | ||||
|---|---|---|---|---|
| 2024 · 2023 | ||||
| Cash flow from operating activities: | ||||
| Net loss | $(44,599) | $(205,842) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization | 6,046 | 7,028 | ||
| Non cash lease expense | 125 | (62) | ||
| Provision for credit losses | 222 | 456 | ||
| Provision for inventory obsolescence | (50) | - | ||
| Change in fair value of warrant liabilities | 1,156 | (6,788) | ||
| Goodwill impairment | - | 112,347 | ||
| IPR&D impairment | - | 107,800 | ||
| Stock-based compensation expense | 8,628 | 11,442 | ||
| Change in fair value of contingent consideration | - | (104,339) | ||
| Acquired in-process research and development | - | 3,000 | ||
| Issuance of common stock for stem-cells to be used in research and development | - | 1,000 | ||
| Issuance of common stock to Palantir as consideration for settlement agreement | 175 | - | ||
| Issuance of common stock to Yorkville for debt extension and SEPA commitment fee | 317 | 712 | ||
| Discounts arising from RWI loan arrangement - related party | - | 2,151 | ||
| Fair value of warrant modification for professional services | - | 403 | ||
| Change in fair value of contingent stock consideration | - | (159) | ||
| Loss on extinguishment of debt | 3,908 | - | ||
| Change in fair value of debt | 694 | 354 | ||
| Non cash interest expense | 3,217 | - | ||
| Other, net | (285) | 2,012 | ||
| Changes in assets and liabilities: | ||||
| Accounts receivable | 1,054 | (118) | ||
| Inventory | 5,653 | (1,605) | ||
| Prepaid expenses and other assets | 109 | 2,179 | ||
| Accounts payable | 1,312 | 6,754 | ||
| Accrued expenses and other liabilities | 7,237 | 1,533 | ||
| Accrued R&D software | (3,500) | 24,161 | ||
| Lease liabilities - operating | 274 | 172 | ||
| Deferred revenue | 312 | 1,065 | ||
| Net cash used in operating activities | (7,995) | (34,344) | ||
| Cash flow from investing activities: | ||||
| Capital expenditures | (105) | (468) | ||
| Proceeds from Sanuwave convertible note receivable | 2,175 | - | ||
| Purchase of acquired in-process research and development | - | (3,000) | ||
| Net cash provided by (used in) investing activities | 2,070 | (3,468) | ||
| Cash flow from financing activities: | ||||
| Proceeds from warrants and short-term debt - related parties | 15,000 | 18,369 | ||
| Proceeds from registered direct offering | - | 9,000 | ||
| Proceeds from the exercise of stock options | - | 304 | ||
| Repayments of short-term debt - unaffiliated | (17,374) | (16,811) | ||
| Proceeds from issuance of short-term debt - unaffiliated | 2,993 | 2,000 | ||
| Payment of SEPA commitment fee | (25) | - | ||
| Repayments of short-term debt - related parties | (106) | - | ||
| Proceeds from PIPE financing | 6,000 | 12,750 | ||
| Proceeds from the sale of common stock in ATM offering | - | 136 | ||
| Payments of PIPE and other issuance costs | - | (1,553) | ||
| Tax withholding on vesting of restricted stock units | (430) | (87) | ||
| Net cash provided by financing activities | 6,058 | 24,108 | ||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 133 | (13,704) | ||
| Cash, cash equivalents and restricted cash at beginning of period | 10,163 | 28,802 | ||
| Cash, cash equivalents and restricted cash at end of period | $10,296 | $15,098 | ||
| Supplemental disclosure of cash flow information: | ||||
| Cash paid for interest | $144 | $1,073 | ||
| Supplemental non-cash investing and financing activities: | ||||
| Property and equipment included in accounts payable and accrued expenses | $(56) | $(752) | ||
| Modification of C.V. Starr warrants in connection with forbearance | $51 | $ | - | |
| Reduction of right-of-use assets and associated lease liabilities - operating due to lease modification | $ | - | $(2,083) | |
| Issuance of RWI warrants in connection with forbearance | $1,162 | $ | - | |
| Issuance of warrants on senior secured bridge loan | $ | - | $2,002 | |
| Reclassification of warrants from liability classified to equity classified | $2,970 | $ | - | |
| PIPE related offering costs included in accrued expenses | $ | - | $(69) | |
| Common stock issued for short-term debt conversion | $ | - | $4,599 | |
| Interest accrued on senior secured loans within long-term debt - related parties | $ | - | $(1,229) | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.